Written by Paola Larrabure, Pharma Content Manager, QuickRx Specialty Pharmacy
Medically reviewed by Julia Kravtsova, PharmD, Head Patient Navigator
Published August 24, 2026. Last updated August 24, 2026.
Educational information only. This article is written for patients and caregivers and is not medical advice, a treatment recommendation, or a substitute for the judgment of your prescriber. Do not start, stop, switch, or change the dose of any medication based on this page. Everolimus is a prescription medication that requires ongoing laboratory monitoring and prescriber supervision. Always follow your own prescriber’s instructions and the FDA-approved labeling dispensed with your prescription.
Is there a generic version of Afinitor?
Yes. Generic everolimus is available in the United States, and Lexidrug lists it in eight oral tablet strengths: 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg.
Everolimus is the active ingredient in Afinitor. Everolimus first received FDA approval on March 30, 2009. Lexidrug’s “Generic Available (US)” field for everolimus reads “Yes.”
What confuses most patients is that “generic everolimus” is not the only non-Afinitor option on the market. Lexidrug lists five US brand names for everolimus:
- Afinitor (tablets: 2.5 mg, 5 mg, 7.5 mg, 10 mg)
- Afinitor Disperz (tablets for oral suspension: 2 mg, 3 mg, 5 mg)
- Torpenz (tablets: 2.5 mg, 5 mg, 7.5 mg, 10 mg)
- Yulithira (tablets: 2.5 mg, 5 mg, 7.5 mg, 10 mg)
- Zortress (tablets: 0.25 mg, 0.5 mg, 0.75 mg, 1 mg)
Generic everolimus is also available as a soluble tablet in 2 mg, 3 mg, and 5 mg, matching the Afinitor Disperz strengths.
A note on substitution. Being listed as an everolimus product does not by itself mean a given product can be substituted for another at the pharmacy counter. Therapeutic equivalence is determined by the FDA’s Orange Book rating, and whether a substitution may be made is further governed by your state’s pharmacy law, your prescriber’s instructions, and your plan’s formulary. Tablets and tablets for oral suspension are not interchangeable, and per Lexidrug the two formulations must not be combined to reach a total dose. Ask your pharmacist which specific product your prescription is written for.
How much does generic everolimus cost?
At the standard 10 mg oncology strength, Lexidrug lists an Average Wholesale Price of $844.64 per tablet for Afinitor and $605.56 to $605.82 per tablet for generic everolimus, a difference of roughly 28 percent.
| Product | 2.5 mg | 5 mg | 7.5 mg | 10 mg |
|---|---|---|---|---|
| Afinitor | $807.58 | $844.72 | $844.69 | $844.64 |
| Torpenz | $665.47 | $696.07 | $696.07 | $696.07 |
| Everolimus (generic) | $578.94 to $605.82 | $605.56 to $605.82 | $605.56 to $605.82 | $605.56 to $605.82 |
| Yulithira | $9.00 | $10.00 | $14.00 | $17.00 |
The transplant-strength products are priced on a different scale. Lexidrug lists Zortress at $13.69 (0.25 mg), $27.43 (0.5 mg), $41.11 (0.75 mg), and $54.74 (1 mg) per tablet, with generic everolimus at those same low strengths listed at $10.00 to $10.57, $20.00 to $21.14, $30.00 to $31.71, and $40.00 to $42.29 respectively.
For the soluble tablets, Lexidrug lists Afinitor Disperz at $803.52 (2 mg), $811.55 (3 mg), and $844.68 (5 mg) per tablet, and generic everolimus soluble tablets at $575.67, $581.44, and $605.16.
What AWP is, and what it is not. Average Wholesale Price is a published benchmark figure, not a retail price and not the amount you will be charged. Per the pricing disclaimer published with the Lexidrug monograph, AWP is provided as a reference price only, a range is shown when more than one manufacturer reports a price, the data should be used for benchmarking purposes only, it should not be used alone to set or adjudicate prices for reimbursement or purchasing, and it should not be considered an exact price for any single product or manufacturer. Medi-Span, the pricing data source, disclaims warranties as to the accuracy of this price data. Pricing data is updated monthly, so the figures above may change after the accessed date shown. Your actual cost depends on your insurance plan, your formulary tier, your deductible and coinsurance, your pharmacy, and your dose. Prices shown are per tablet, not per month.
Why is everolimus so expensive?
Everolimus is priced per tablet rather than per milligram at the oncology strengths, which means a dose reduction from 10 mg to 2.5 mg does not meaningfully reduce the cost of the prescription.
This is visible directly in the AWP figures above. Afinitor is listed at $807.58 for a 2.5 mg tablet and $844.64 for a 10 mg tablet, a difference of about 4 percent for four times the drug. Generic everolimus shows the same pattern, with 5 mg, 7.5 mg, and 10 mg all listed at $605.56 to $605.82.
The transplant strengths behave differently. There, Lexidrug’s listed prices rise roughly in proportion to the dose, from $10.00 at 0.25 mg to $40.00 at 1 mg for generic everolimus.
This matters for patients because dose reductions are common with everolimus. Lexidrug’s dosage modification tables call for reducing to 50 percent of the previous dose for a range of grade 3 adverse reactions, and for reducing to 7.5 mg or 5 mg once daily in mild hepatic impairment and to 5 mg or 2.5 mg in moderate hepatic impairment. A patient who has been dose-reduced for tolerability should not expect the reduction alone to lower what the prescription costs.
“Patients assume a dose reduction will cut their bill. At these strengths it usually does not, because the price sits with the tablet, not the milligram. That is the conversation I have most often, and it is the one nobody warns them about.”
Julia Kravtsova, PharmD, Head Patient Navigator, QuickRx Specialty Pharmacy
Why didn’t the generic lower what I pay?
Generic availability lowers a drug’s benchmark price, but what you pay out of pocket is set by your insurance plan’s formulary tier and cost-sharing rules, which often do not change when a generic arrives.
Several things can keep a patient’s out-of-pocket cost high even after a generic exists:
- Specialty tier placement. Oral oncology and immunosuppressant drugs are frequently placed on a specialty tier where the patient owes a percentage of the drug cost rather than a flat copay. A percentage of a lower price is still a large number when the underlying price is in the hundreds of dollars per tablet.
- Formulary preference. A plan may prefer one everolimus product over another, and the preferred product is not always the one with the lowest published price.
- Prior authorization. Coverage may require documentation of diagnosis, prior therapy, or both before the plan will pay anything.
- Deductible timing. Early in a plan year, a patient may be paying the full negotiated cost until the deductible is met.
- Limited distribution. Some products are dispensed only through specific pharmacies, which affects which price your plan applies.
“A generic existing and a generic lowering your copay are two different things. I verify the benefit before the patient fills, because the plan’s tier decides the number, not the price list.”
Julia Kravtsova, PharmD, Head Patient Navigator, QuickRx Specialty Pharmacy
This is the part of the cost question that a published price list cannot answer, because the answer depends on your specific plan. A specialty pharmacy can run a benefits verification and tell you what your plan will actually charge for the specific everolimus product on your prescription before you fill it.
QuickRx verifies benefits, handles prior authorizations, and helps patients enroll in the financial assistance programs they qualify for. Eligible patients may pay $0. To see what applies to your situation, read our Afinitor (everolimus) copay assistance page or call (917) 830-2525.
Eligibility criteria apply to all financial assistance programs and are set by the program sponsor, not by QuickRx. Not every patient qualifies. Manufacturer copay programs generally exclude patients enrolled in Medicare, Medicaid, TRICARE, or other federal or state healthcare programs. Benefit verification results reflect plan information available at the time of the check and can change. QuickRx does not guarantee coverage, approval, or any particular out-of-pocket amount.
More about everolimus
This article covers cost, generic availability, and pricing only. Side effects, dosing, administration, and how everolimus works are covered in full on our dedicated everolimus pages.
- Guide to everolimus: what it is, the cancers and transplant indications it treats, how it works, whether it is chemotherapy, how it is taken, side effects, and dietary restrictions.
- Everolimus: Afinitor vs. Zortress explained: why the same active ingredient carries two brand names, and how the indications and strengths differ.
- Afinitor: what patients and caregivers need to know: administration, dietary considerations, lifestyle adjustments, and caregiver guidance.
- Understanding Zortress: a guide for new transplant patients.
Frequently asked questions about generic everolimus
Generic everolimus contains the same active ingredient as Afinitor, everolimus. Lexidrug lists generic everolimus oral tablets in 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg strengths. Whether a specific generic product may be substituted for Afinitor at the pharmacy depends on the FDA Orange Book therapeutic equivalence rating, your state’s pharmacy substitution law, your prescriber’s instructions, and your plan’s formulary. Ask your pharmacist which product your prescription is written for.
Lexidrug publishes Average Wholesale Price per tablet, not per month. At the 10 mg strength, Lexidrug lists $844.64 per tablet for Afinitor and $605.56 to $605.82 per tablet for generic everolimus, accessed July 17, 2026. AWP is a published benchmark, not a retail price and not what you will be charged. What you pay depends on your plan’s formulary tier, deductible, and coinsurance, on your dose, and on your pharmacy. Call (917) 830-2525 for a benefits verification on your specific prescription.
At the oncology strengths, everolimus is priced per tablet rather than per milligram. Lexidrug lists Afinitor at $807.58 for a 2.5 mg tablet and $844.64 for a 10 mg tablet, a difference of about 4 percent for four times the drug. Generic everolimus shows the same flat pattern across 5 mg, 7.5 mg, and 10 mg. The transplant strengths, 0.25 mg through 1 mg, are priced roughly in proportion to dose instead.
Usually not at the oncology strengths. Because everolimus is priced per tablet at 2.5 mg through 10 mg, a reduction from 10 mg to 5 mg generally does not cut the cost of the prescription in half. Dose reductions with everolimus are common, since Lexidrug’s dosage modification tables call for reducing to 50 percent of the previous dose for a range of grade 3 adverse reactions and for reduced dosing in hepatic impairment. Talk to your pharmacy about what your plan will charge at your new dose.
Not necessarily. Generic availability lowers a drug’s published benchmark price, but out-of-pocket cost is determined by your plan. Specialty tier placement, coinsurance instead of a flat copay, formulary preference, prior authorization, deductible timing, and limited distribution requirements can all keep costs high after a generic launches. A benefits verification on your specific prescription is the only way to know. Call QuickRx at (917) 830-2525.
References
- Everolimus. Lexidrug. Waltham, MA: UpToDate Inc. Accessed July 17, 2026. Dosing, dosage forms, US pricing (Average Wholesale Price), labeled indications, adverse reactions, administration, storage, monitoring parameters, drug and food interactions, and generic availability data in this article are drawn from this monograph. https://online.lexi.com/
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
- MedlinePlus. Everolimus. Bethesda, MD: National Library of Medicine. https://medlineplus.gov/druginfo/meds/a609032.html?utm_source=chatgpt.com
- Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529. doi:10.1056/NEJMoa1109653. PubMed 22149876
- Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456. PubMed 18653228
- Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125-132. PubMed 23158522
- French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153-2163. PubMed 27613521
- Arena C, Troiano G, Zhurakivska K, Nocini R, Lo Muzio L. Stomatitis and everolimus: a review of current literature on 8,201 patients. Onco Targets Ther. 2019;12:9669-9683. doi:10.2147/OTT.S195121. PubMed 31814732
About this article. Written by Paola Larrabure, Pharma Content Manager, QuickRx Specialty Pharmacy. Medically reviewed by Julia Kravtsova, PharmD, Head Patient Navigator. Published August 24, 2026. Last updated August 24, 2026. Pricing figures reflect the Lexidrug monograph as accessed July 17, 2026 and are updated monthly by the data source. QuickRx Specialty Pharmacy does not manufacture everolimus and is not affiliated with, endorsed by, or sponsored by any manufacturer named in this article. Manufacturer names are used for identification purposes only. This page does not constitute an offer, guarantee, or promise of coverage, pricing, or program eligibility.
